[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371250-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371250-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tumor-mutational-burden-and-survival-on-immune-checkpoint-inhibition-in-8000-patients-across-24-cancer-types","Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types","","Background addresses uncertainty about tumor mutational burden (TMB) clinical applicability across cancer types, driven by inconsistent TMB measurements between platforms. Using a large real-world dataset with validated survival endpoints, this study evaluates clinical validity of TMB measurement based on the FDA-approved FoundationOneCDx test in more than 8000 patients across 24 cancer types receiving single-agent immune checkpoint inhibition.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tumor-mutational-burden-and-survival-on-immune-checkpoint-inhibition-in-8000-patients-across-24-cancer-types/371250/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tumor-mutational-burden-and-survival-on-immune-checkpoint-inhibition-in-8000-patients-across-24-cancer-types/371250.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is tumor mutational burden (TMB) clinical applicability uncertain across cancer types?","Question",{"text":63,"@type":64},"TMB applicability is uncertain due to inconsistency between TMB measurements from different platforms and variability in prior study designs and outcome measures.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients and survival endpoints defined in this study?",{"text":68,"@type":64},"Patients with advanced-stage cancers across 24 types treated with single-agent anti–PD(L)1 therapy were included, using de-identified electronic health record data and real-world overall survival validated against the national death index.",{"name":70,"@type":61,"acceptedAnswer":71},"What was the main relationship between TMB level and overall survival?",{"text":72,"@type":64},"After adjusting for prespecified clinical and demographic factors, higher TMB was significantly associated with improved real-world overall survival across tumor types, with strong benefit particularly at higher TMB thresholds.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371250,1790981568,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Open access  \nTo cite: Gandara DR, Agarwal N, Gupta S, et al. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. Journal for ImmunoTherapy of Cancer 2025;13:e010311 . doi:10.1136/jitc-2024-010311  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-010311](jitc-2024-010311)) .  \nAccepted 26 November 2024  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Ryon P Graf;  \n[rgraf@foundationmedicine.com](rgraf@foundationmedicine.com)  \nOriginal research  \nTumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types  \nDavid R Gandara  ,1 Neeraj Agarwal  ,2 Shilpa Gupta,3 Samuel J Klempner,4 Miles C Andrews  ,5 Amit Mahipal,6 Vivek Subbiah,7 Ramez N Eskander,8 David P Carbone  ,9 Jonathan W Riess,10 Sarah Sammons,11 Jeremy Snider,12 Lilia Bouzit,12 Cheryl Cho-Phan,12 Megan Price,12 Gerald Li,13  \nJulia C F Quintanilha,13 Richard Sheng Poe Huang  ,13 Jeffrey S Ross,13 David Fabrizio,13 Geoffrey R Oxnard,14 Ryon P Graf  15  \nABSTRACT  \nBackground There is uncertainty around clinical applicability of tumor mutational burden (TMB) across cancer types, in part because of inconsistency between TMB measurements from different platforms. The KEYNOTE 158 trial supported United States Food and Drug Administration (FDA) approval of the Foundation Medicine test (FoundationOneCDx) at TMB≥10 mut/ Mb as a companion diagnostic (CDx) for single-agent pembrolizumab in second+line. Using a large realworld dataset with validated survival endpoint data, we evaluated clinical validity of TMB measurement by the test in over 8000 patients across 24 cancer types who received single-agent immune checkpoint inhibitor (ICI) .  \nMethods Patients with advanced-stage cancers from 24 cancer types treated with single-agent anti-PD(L)1 therapy in standard-of-care settings were included. Deidentified data from electronic health records from approximately 280 cancer treatment facilities were captured into a clinico-genomic database. This study used the TMB algorithm from the FDA-approved test supporting solid tumor CDx and composite mortality variable validated against the national death index: real-world overall survival (rwOS). Following a prespecified analysis plan, rwOS by TMB level was assessed using Cox PH models adjusted for Eastern Cooperative Oncology Group performance status, prior treatment, microsatellite instability, sex, age, opioid rxpretherapy, and socioeconomic assessment.  \nResults 8440 patients met inclusion criteria. Adjusting for aforementioned factors, increasing TMB was significantly associated with rwOS across tumor types; HRs (95% CIs) relative to TMB\u003C5: TMB 5 to \u003C10: 0.95 (0 .89 to 1.02), TMB 10 to \u003C20: 0.79 (0.73 to 0.85), TMB≥20: 0.52 (0.47 to 0 .58) . For individual cancer types with prespecified statistical power, adjusted rwOS comparing TMB≥10 vs TMB\u003C10 significantly favored TMB≥10 in 9 of 10 cancer types. In microsatellite stable subcohorts (except colorectal cancer), TMB≥10 remained associated with enriched ICI benefit. Exploratory assessments of patients receiving ICI+chemotherapy (n=4369) observed more favorable rwOS only in TMB≥20 .  \nConclusions Across >8000 patients treated with singleagent ICI, and within individual cancer types with sufficient power, elevated TMB based on the FDA-approved CDx  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Tumor mutational burden (TMB) has been investigated in many studies. However, considerable variability in assays and TMB algorithms, inconsistencies of prior study designs, and validity of clinical outcome measures have stymied generalizability of TMB clinical applicability.\u003Cbr>WH","cbCaickHbqVYATKu","https://ap.wps.com/l/cbCaickHbqVYATKu","pdf",2408827,13,"English","# Background\n# Methods\n# Results\n# Conclusions\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy\n# Introduction","[{\"question\":\"Why is tumor mutational burden (TMB) clinical applicability uncertain across cancer types?\",\"answer\":\"TMB applicability is uncertain due to inconsistency between TMB measurements from different platforms and variability in prior study designs and outcome measures.\"},{\"question\":\"How were patients and survival endpoints defined in this study?\",\"answer\":\"Patients with advanced-stage cancers across 24 types treated with single-agent anti–PD(L)1 therapy were included, using de-identified electronic health record data and real-world overall survival validated against the national death index.\"},{\"question\":\"What was the main relationship between TMB level and overall survival?\",\"answer\":\"After adjusting for prespecified clinical and demographic factors, higher TMB was significantly associated with improved real-world overall survival across tumor types, with strong benefit particularly at higher TMB thresholds.\"}]","Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types | PDF",1790191620,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa1edca8762df7768b069c56b68fd4b4.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98a90bfe8eec183573e6e9d42fe8e406.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb4245e3ab37367aec1df3bd96609fd5.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/050ea4ff8b7a18be2f2ce0e6e72bfd91.webp",980,1306]